Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, Janson ET, Garresori H, Hofsli E, Kersten C, Elvebakken H, Pfeiffer P, Morken S, Assmus J, Lothe IMB, Tabaksblat E, Knigge U, Couvelard A, Perren A, Langer SW (2025)
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Br J Cancer (in press)
DOI 10.1038/s41416-025-03054-w, PubMed 40382522

Sodergren SC, Edwards R, Krishnatry R, Guren MG, Dennis K, Franco P, de Felice F, Darlington AS, Vassiliou V (2025)
Improving our understanding of the quality of life of patients with metastatic or recurrent/persistent anal cancer: a systematic review
Support Care Cancer, 33 (6), 475
DOI 10.1007/s00520-025-09520-8, PubMed 40372578

Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D (2025)
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
J Clin Oncol, JCO2301965 (in press)
DOI 10.1200/JCO.23.01965, PubMed 40354592